The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe (Q45170003)

10 December 2017

title

The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe (English)

1 reference

10 December 2017

1 reference

Joseph L Kuti

1 reference

10 December 2017

David P Nicolau

1 reference

10 December 2017

Robert G Masterton

1 reference

10 December 2017

Philip J Turner

series ordinal

1 reference

10 December 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

Journal of Antimicrobial Chemotherapy

10 December 2017

published in

1 reference

10 December 2017

1 reference

10 December 2017

1 reference

10 December 2017

page(s)

71-77

1 reference

Appropriate antimicrobial treatment in nosocomial infections—the clinical challenges

10 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH511

Appropriate empirical antibacterial therapy for nosocomial infections: getting it right the first time

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH511

Unit differences in pathogen occurrence arising from the MYSTIC program European database (1997-2000).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH511

The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on Antibiotic Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH511

Determining the value of antimicrobial surveillance programs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH511

Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH511

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH511

MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from Europe: comparison of antibiotic susceptibilities between countries and centre types. MYSTIC Study Group (European centres only).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH511

Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH511

Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH511

Statistical methods for assessing agreement between two methods of clinical measurement

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH511

Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH511

Breakpoints: current practice and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH511

Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH511

Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH511

Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: In vitro and animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH511

Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH511

Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH511

Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH511

Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH511

Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH511

Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH511

Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH511

Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of escherichia coli, klebsiella pneumoniae, acinetobacter baumannii and pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH511

In Vitro Susceptibilities of Gram-Negative Bacteria Isolated from Hospitalized Patients in Four European Countries, Canada, and the United States in 2000-2001 to Expanded-Spectrum Cephalosporins and Comparator Antimicrobials: Implications for Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH511

Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48,440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2001).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH511

21 January 2018

Identifiers

DOI

10.1093/JAC/DKH511

1 reference

10 December 2017

1 reference